NCT01874028View on ClinicalTrials.gov

A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Wilson's Disease

Interventions

DRUG

trientine dihydrochloride

Patients will take their normal prescribed dose (x1) of trientine dihydrochloride 300mg

Trial Locations (1)

69120

Universitätsklinik Heidelberg, Heidelberg

Sponsors

Collaborators (1)

Aptiv Solutions

All Listed Sponsors

collaborator

Aptiv Solutions

INDUSTRY

lead

Univar BV

INDUSTRY

NCT01874028 - A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients | Biotech Hunter | Biotech Hunter